The continuing objectives of this amended grant are to promote and augment the development of a basic cancer research center devoted to collaborative, innovative investigation at a fundamental level with an eye to future clinical cancer research endeavors. Scientists from different backgrounds and different academic departments are coordinating their on-going research efforts to mount a frontal attack on the various aspects of cancer research. Efforts will be concentrated in five research programs, each under the direction of a senior scientist, as follows: Program 1: Cellular Functions and Growth Control: Intracellular Mechanisms; Program 2; Cell structure, Growth and Regulation; Program 3: Control of Hematopoietic Cell Differentiation and Proliferation; Program 4: Growth and Differentiation of Mammalian Endocrine Cells; Program 5: Antigen Recognition and Cellular Activation in Immune Responses. Most of the scientists in each of these five programs have had longstanding collaborative research programs. It is our intention to expand these efforts of existing staff investigators and to recruit new investigators who can bring fresh ideas and new techniques into these collaborative research efforts. The Cancer Research Center will provide the environment for interplay among staff investigators of all five programs, who will be using advanced central research facilities. The NCI Cancer Centers staff has justifiably ruled that we are a Basic Cancer Research Center, but with their encouragement, we shall continue independent development of clinical cancer research initiatives promoted entirely by local funds. Accomplishments during the first three years of CCSG support include: increase in Staff Investigators from 60 to 80; recruitment of seven New Investigators; doubling use by Staff Investigators of Shared Core Research Facilities; renewal of one and acquisition of another program-project grant; acquisition and renovation of new Cancer Center laboratories; development of a new Program in Cancer Immunology; and major expansion of Cancer Center seminars and symposia for greater interaction among Staff Investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA044579-06S1
Application #
2091520
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1987-07-01
Project End
1995-07-31
Budget Start
1993-08-20
Budget End
1995-07-31
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Virginia
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Carlton, Anne L; Illendula, Anuradha; Gao, Yan et al. (2018) Small molecule inhibition of the CBF?/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol 149:350-360

Showing the most recent 10 out of 539 publications